Get 50% OFF This Monsoon!
Camlin Fine Sciences
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Camlin Fine Chemicals Ltd is one of the India's leading manufacturers and exporters of Bulk Drugs, Fine Chemicals and Food Grade products. The company manufactures active pharmaceutical ingredients (API's), food antioxidants and sweeteners. They operate in two business divisions, namely Food Ingredients Division and Industrial products Division. The company's products have applications in processed foods, edible oils, paints, polymers, alternative fuels (biodiesel), rubber, health, and pharmaceuticals.
The company has a strong research and development which is focused on bringing in continual improvements on process and products, backward integration and developing innovative products. The research and development is equipped with comprehensive and updated instrumentation for conducting quality analysis, stability studies. The research and development also is equipped to conduct application studies on stability index of edible oils and Bio-diesel.
Camlin Fine Chemicals Ltd was originally incorporated on November 30, 1993 as a private limited company with the name of Camlicon Consultants Pvt Ltd. In April 2006, the main object of the company was altered to enable the company to pursue business in Fine Chemicals. They launched a new product namely, 'Sucralose' which is a synthetic sweetener with large demand and attractive price.
In June 1, 2006, the name of the company was changed from Camlicon Consultants Pvt Ltd to Camlin Fine Chemicals Pvt Ltd. As per the scheme of arrangement, the fine chemicals division of Camlin Ltd was de-merged and transferred to the company with effect from July 01, 2006. In August 11, 2006, the company was converted into public limited company and the name was changed to Camlin Fine Chemicals Pvt Ltd.
The company entered into a joint venture with Viachem LLC USA on 51:49 basis and set up a company namely, Dulcette Technologies LLC for marketing Sucralose, Aspartame and Acesulfame-K and their blends in USA, Canada and Mexico. In March 30, 2007, the equity shares of the company were listed on the Bombay Stock Exchange (BSE).
During the year 2007-08, the company increased the production capacity of Chemical & Chemical Products from 1,636 Ltrs/Kgs to 2,476 Ltrs/Kgs. The company acquired the control of Sangam Laboratories Ltd by acquiring 60% of the paid up equity share capital of the company. They invested Rs 5 lakh for controlling interest in the Equity Share Capital of Chemolutions Chemicals Ltd.
In February 2008, the company entered into a joint venture agreement with Advanced Aerospace Technologies Inc., USA' to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets. During the year 2008-09, the company expanded the production capacity of Chemical & Chemical Products from 2,476 Ltrs/Kgs to 2,548 Ltrs/Kgs. The company invested Rs 25.50 lakh in Fine Lifestyle Brands Ltd and Rs.5.10 lakh in Fine Renewable Energy Ltd, which represents 51% of equity share capital of each of them. They further invested Rs 92.32 lakh in the share capital of their present subsidiaries, namely Sangam Laboratories Ltd, Chemolutions Chemicals Ltd and Dulcette Technologies LLC, USA.
During the year 2009-10, the company expanded the production capacity of Chemical & Chemical Products from 2,458 Ltrs/Kgs to 3,500 Ltrs/Kgs. They are entering the field of Bio technology products and first patented, biotechnology based Natural shelf life enhancing formula for increasing shelf life of Natural farm produce, like fruits, vegetables and flowers.
During the year 2011, Chemolutions Chemicals Limited, Fine Lifestyle Brands Limited and Fine Renewable Energy Limited ceased to be subsidiaries of the Company. The Hon'ble High Court Bombay, vide order dated 21st April, 2011 approved Scheme of Amalgamation for merger of Sangam Laboratories Limited, a 100% owned subsidiary with the Company. W.e.f. 27th August, 2011 name of the Company was changed from Camlin Fine Chemicals Limited to Camlin Fine Sciences Limited.
The establishment of two major business divisions, namely, Food and Industrial Products was completed. The Company expanded its manufacturing capacity of the food antioxidants, Ascorbyl Palmitate, TBHQ and BHA in 2012-13. In January 2016, it started operations in Central America with the launch of CFS Antioxidantes De Mexico, S.A. de C.V., a 100% subsidiary of Camlin Fine Sciences Ltd., acquired 65% stake in Dresen Química S.A.P.I de C.V, a leading food and feed blend company in Mexico; launched CFS North America, LLC, a 100% owned subsidiary of CFS for manufacturing and selling of customised antioxidant blends; launched Evanil, ethyl vanillin for food and bakery industry.
On 15th April, 2016, a 100% wholly owned subsidiary CFS International Trading (Shanghai) Ltd. was incorporated in China (Shanghai) pilot free trade zone to manufacture and deal in speciality chemicals. On 22nd March, 2017, Chemolutions Chemicals Limited (CCL) allotted 62,67,003 equity shares on preferential basis to the Company. Post allotment, the shareholding of Company in CCL was 94.08% and CCL became the subsidiary of the Company. In July 2017, Company through its wholly owned stepdown subsidiary viz. CFS Europe S.p.A. acquired 51% stake in CFS Wanglong Flavours (Ningbo) Co. Ltd. erstwhile Ningbo Wanglong Flavors and Fragrances Company Limited. In April 2018, Company signed a joint venture contract with Pahang Pharma (S) Pte. Ltd., Singapore (Pahang) for incorporating a holding company, shareholding in the proportion of 51:49, named CFS Pahang Asia Pte. Ltd. in Singapore.
In 2019, the Company reverse merged its wholly owned subsidiary in Mauritius viz., CFCL Mauritius Private Limited into CFS Europe Spa, Italy effective 25th June, 2019 and resultant to this merger, CFS Europe Spa became a wholly-owned subsidiary. The reverse merger of CFS Antioxidnates De Mexico De CV with Dresen Quimica SAPI De CV was effective 31st January, 2019 and resultant to reverse merger, CFS Antioxidantes De Mexico S.A. de. C.V. ceased to be the wholly-owned subsidiary of the Company from the aforementioned date. As a part of this initiative, Company acquired a company situated in Southern part of India, namely, AlgalR Nutrapharms Private Limited (AlgalR) which manufactures oils containing Omega 3 Fatty Acids. The company embarked upon its largest greenfield expansion in 2018 in Dahej, Gujarat for a green-technology-based DiPhenol plant for a 10,000 MT Di-Phenol facility. And in September 2020, it announced the commercial production of Hydroquinone and Catechol.
During the financial year 2021-22, AlgalR NutraPharms Private Limited and CFS De Mexico Blends SAPI De CV became subsidiaries and Fine Lifestyle Brands Limited has ceased to be a Associate of the Company.
Camlin Fine Sciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Camlin Fine Sciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Camlin Fine Sciences is valued compared to its competitors.
Camlin Fine Sciences PE ratio helps investors understand what is the market value of each stock compared to Camlin Fine Sciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Camlin Fine Sciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Camlin Fine Sciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Camlin Fine Sciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Camlin Fine Sciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Camlin Fine Sciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Camlin Fine Sciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Camlin Fine Sciences helps investors get an insight into when they can enter or exit the stock. Key components of Camlin Fine Sciences Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Camlin Fine Sciences shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Camlin Fine Sciences ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Camlin Fine Sciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Camlin Fine Sciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Camlin Fine Sciences .
The balance sheet presents a snapshot of Camlin Fine Sciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App